After OncoSec (ONCS) reported updated data for the registrational KEYNOTE-695 study evaluating TAVO plus Merck’s (MRK) Keytruda, Piper Jaffray analyst Edward Tenthoff noted that TAVO’s ORR improved and called the fact that TAVO resensitized anti-PD-1 progressers “impressive.” He reiterates an Overweight and $3 price target on OncoSec shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.